FORMULATION AND EVALUATION OF RABEPRAZOLE SODIUM AND DOMPERIDONE PELLETS

The aim of present study was to formulate and evaluate Rabeprazole sodium and Domperidone pellets for the treatment of gastro esophageal reflux disease. Modified release drug delivery systems were capable of drug release when and where it requires. In the present study delayed release Rabeprazole sodium pellets were prepared by a drug layering, seal coating and enteric coating by using eudragit L100 55 as enteric coating material different weight gains were developed and evaluated for optimized formula and Sustained release Domperidone pellets were prepared by drug layering, sustained release coating with ethyl cellulose 7 cps as sustained release material. The formulated coated pellets were evaluated for angle repose, bulk density, tapped density, hausener ratio, Carr’s index, FTIR, DSC. Moisture content. In vitro release and acid-resistance studies were carried out in simulated gastric fluid and simulated intestinal fluid, respectively. The results indicated that Rabeprazole sodium pellets with seal coat of 10 % (F13) formula and 30% of enteric coat with eudragit L 100 55 (F30) formula showed good acid resistance and drug release. Domperidone pellets with 10 % (F9) and 12 % (F10) formulas of extended release coating with ethyl cellulose were showed required sustained action. The optimized formulations were evaluated for different release kinetics and found that Rabeprazole delayed release pellets were following First order and Korsemeyer-peppas equation Hence the release mechanism was by concentration dependent dissolution process. Domperidone pellets were following First order and Higuchi’s equation Hence the release mechanism was by concentration dependent diffusion process. F20 formula of rabeprazole pellets and F10 of formula domperidone pellets were showed required release characteristics were selected and filled in to the capsules.